REDWOOD CITY, Calif., June 24, 2026
Revolution Medicines announced that new clinical data from its innovative RAS(ON) inhibitor portfolio will be presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2026, taking place July 1–4 in Munich, Germany. The company will showcase findings from multiple studies evaluating zoldonrasib (RMC-9805) and daraxonrasib (RMC-6236) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and difficult-to-treat forms of cancer. The presentations underscore the company’s commitment to advancing targeted therapies designed to address RAS-driven tumors, which account for a significant proportion of pancreatic cancer cases worldwide.
Zoldonrasib Combination Studies Show Promise in Metastatic PDAC
A major highlight of the congress will be two oral presentations featuring data from ongoing Phase 1/2 clinical trials evaluating zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor. The first presentation will focus on the combination of zoldonrasib with chemotherapy as a first-line treatment for patients with RAS G12D metastatic pancreatic adenocarcinoma. The second presentation will evaluate zoldonrasib in combination with daraxonrasib, a multi-selective RAS(ON) inhibitor, in patients who have already received one or more prior lines of therapy. These studies are designed to determine whether targeting KRAS-driven disease through combination approaches can improve treatment outcomes and potentially extend survival for patients with advanced pancreatic cancer.
Phase 3 RASolute Program Expands Development Strategy
In addition to clinical efficacy updates, Revolution Medicines will present two Phase 3 trials-in-progress posters from its global RASolute development program. The RASolute 303 study is evaluating daraxonrasib as both a monotherapy and in combination with gemcitabine and nab-paclitaxel versus standard-of-care chemotherapy in newly diagnosed metastatic PDAC patients. Meanwhile, RASolute 304 is investigating daraxonrasib as an adjuvant treatment for patients who have undergone surgical resection and completed perioperative chemotherapy. These large-scale studies are expected to provide critical evidence regarding the role of RAS(ON) inhibition across multiple stages of pancreatic cancer treatment and could support future regulatory submissions if successful.
Advertisement
Advancing Precision Oncology Through RAS(ON) Innovation
Revolution Medicines continues to build one of the industry’s most comprehensive pipelines focused on RAS-addicted cancers, targeting mutations that have historically been difficult to treat. The company’s portfolio includes daraxonrasib (RMC-6236), elironrasib (RMC-6291), zoldonrasib (RMC-9805), and RMC-5127, each designed to selectively inhibit specific oncogenic RAS variants. Additional investigational candidates targeting Q61H and G13C mutations are also progressing through development. By leveraging its proprietary RAS(ON) platform, Revolution Medicines aims to provide highly targeted treatment options for patients whose cancers are driven by specific genetic mutations. The upcoming ESMO presentations are expected to offer important insights into the potential of next-generation RAS-targeted therapies and reinforce the growing role of precision medicine in transforming pancreatic cancer care.
Source: Revolution Medicines press release
